Blog Archives

Ivosidenib (Tibsovo) for AML-patients with IDH1-mutations

July 22, 2018 – The American Food and Drug Administration (FDA) just approved Ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the IDH1 gene.  

Read more ›

Tags: , , , , , , , , , , , , , ,

Enasidenib (Idhifa): Targeted treatment for relapsed or refractory AML

August 02, 2017 – This is another cornerstone in the fight against acute myeloid leukemia (AML): The American Food and Drug Administration (FDA) just approved Enasidenib (Idhifa) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.

Read more ›

Tags: , , , , , , , , ,

LeukoStrat CDx FLT3 Mutation Assay: New entry in the field of companion tests

 

April 30, 2017 – The American Food and Drug Administration (FDA) just approved Midostaurin (Rydapt) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who carry particular genetic mutations in the FLT3 (CD135) gene,

Read more ›

Tags: , , , , , , , , , ,

Gemtuzumab Ozogamicin [Mylotarg]: Market Withdrawal

June 21, 2010 –  FDA notified healthcare professionals that results from a recent clinical trial raised new concerns about the product’s safety, and the drug failed to demonstrate clinical benefit to patients enrolled in trials.

Background:

Gemtuzumab Ozogamicin [Mylotarg], indicated for treatment of acute myeloid leukemia (AML),

Read more ›

Tags: ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • How hormone therapy slows progression of atherosclerosis September 28, 2020
    As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis. A study based on Early Versus Late Intervention Trial With Estradiol (ELITE) data evaluated the underlying mechanism of such benefit and will be presented during the […]
  • Newer Type 2 diabetes medications have heart and kidney disease benefits, too September 28, 2020
    Two newer classes of medications used to treat Type 2 diabetes have been shown to protect patients against heart disease and chronic kidney disease, in addition to their ability to help manage blood glucose. Patients with Type 2 diabetes have a high rate of chronic kidney and cardiovascular disease and more serious complications; these newer […]
  • Cannabis use for menopause symptom management September 28, 2020
    CLEVELAND, Ohio (September 28, 2020)--As legislation relaxes regarding cannabis, it is being used to manage numerous chronic health conditions and mood symptoms. A new study indicates that a growing number of women are either using cannabis or want to use it for the management of bothersome menopause symptoms. Study results will be presented during the […]
  • Advances in nonhormone therapies provide women with more options for managing hot flashes September 28, 2020
    Although many women manage menopause symptoms with hormone therapy, increasing numbers of women are considering nonhormone options. Dr. Susan Reed from the University of Washington School of Medicine is a featured speaker during the 2020 Pre-Meeting Symposium of The North American Menopause Society (NAMS) and will discuss the latest advances in nonhormone hot flash management. […]
  • 1 in 3 parents plan to skip flu shots for their kids during COVID-19 pandemic September 28, 2020
    The pandemic doesn't seem to be changing parents' minds about the importance of the flu vaccine.
Top